Microsatellite instability (MSI) status, tumor mutational burden (TMB), genomic loss of heterozygosity, prediction of germline status, and genomic signature were determined with algorithm-based analysis.<h4>Results</h4>Clinically advanced cancers (0.43% of 1993) featured FANCC GA; 27 of these FANCC-mutated tumors (20 males, mean age 57) were RT (0.35% of 7668 RT). This evidence concerns the gene FANCC and cancer.